Turning on two specific body switches—one for glucagon and one for GLP-1—helps burn more energy without raising blood sugar, because one speeds up metabolism and the other keeps blood sugar in check.
Mechanism
Synthesis from 3 studies
This drug makes your body burn fat by turning on two switches: one that tells fat cells to release energy, and another that tells your liver and brown fat to turn that energy into heat. At the same time, it helps your pancreas release just enough insulin and slows down digestion so your blood sugar...
Most probable mechanism
A drug that activates two specific receptors in the body first tells fat cells to break down stored fat into fatty acids. These fatty acids travel to the liver, which uses them to produce energy and signaling molecules that tell brown fat to burn more calories as heat. At the same time, the drug tells the pancreas to release just the right amount of insulin to keep blood sugar from rising too high, and slows down how fast food leaves the stomach, preventing sugar spikes. Together, this makes the body burn more energy without causing dangerous blood sugar levels.
Glucagon receptor activation on white adipose tissue triggers intracellular cAMP/PKA signaling, leading to phosphorylation of hormone-sensitive lipase and hydrolysis of triglycerides into free fatty acids and glycerol.
Released free fatty acids enter the bloodstream and are taken up by the liver, where they activate PPARα and induce expression of CPT1a, driving mitochondrial fatty acid oxidation and ketogenesis.
Hepatic fatty acid oxidation and ketogenesis stimulate transcription and secretion of FGF21, which acts as a hepatokine to promote UCP1 expression in brown adipose tissue and beige adipocytes.
FGF21 and sympathetic nervous system activation induce UCP1 protein expression in brown adipocytes, uncoupling mitochondrial respiration to dissipate energy as heat, increasing whole-body energy expenditure.
GLP-1 receptor activation on pancreatic β-cells enhances glucose-stimulated insulin secretion via cAMP/PKA signaling, while free fatty acids potentiate this effect to maintain glucose tolerance.
GLP-1 receptor activation in the gastrointestinal tract slows gastric emptying, reducing the rate of dietary glucose absorption and preventing postprandial hyperglycemia.
Less supported by current evidence, but not ruled out
Free fatty acids released from fat tissue attract specific immune cells that release signals causing white fat cells to take on heat-burning properties similar to brown fat, adding to overall calorie burning.
Free fatty acids released from white adipose tissue act as chemoattractants for eosinophils and invariant natural killer T cells.
Infiltrating eosinophils and iNKT cells secrete IL-4 and IL-13, which polarize macrophages toward an M2 phenotype.
M2 macrophages secrete factors that induce UCP1 expression in white adipocytes, promoting their conversion to thermogenic beige adipocytes.
Fat tissue releases a hormone called adiponectin in response to the drug, which signals the liver to burn more fat and produce fewer new fats, helping the body shift toward using fat for energy.
Glucagon and GLP-1 receptor activation increases adiponectin secretion from white adipose tissue.
Adiponectin binds to receptors on hepatocytes, activating AMPK and PPARα signaling pathways.
PPARα activation upregulates genes involved in fatty acid oxidation, enhancing hepatic lipid clearance and reducing steatosis.
Evidence from Studies
Supporting (3)
Community contributions welcome
The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
1974-LB: The Molecular Basis of Survodutide (BI456906) Glucagon/GLP-1 Receptor Dual Agonism
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.